Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with potential blockbuster sales. The deal provides Gilead with CymaBay's lead experimental drug, seladelpar, which is under FDA review for potential treatment of primary biliary cholangitis. This acquisition comes as Gilead seeks growth beyond its core HIV business and amidst recent setbacks in clinical trials for other drugs.
Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment, seladelpar, with potential blockbuster sales. The deal comes as Gilead seeks growth beyond its core HIV business and follows setbacks in clinical trials for other drugs. The acquisition is expected to complement Gilead's portfolio of liver disease treatments and is anticipated to be neutral to Gilead's earnings in 2025.
Gilead has announced its acquisition of CymaBay Therapeutics for $4.3 billion, just ahead of the FDA's expected decision on CymaBay's rare liver disease drug candidate, selexipag. The deal, valued at $32.50 per share, represents a 27% premium to CymaBay's closing price on Friday. CymaBay's drug has shown promise in treating primary biliary cholangitis, a rare chronic disease that primarily affects women in the US, with the FDA's approval decision deadline set for August 14.
Gilead Sciences has announced the acquisition of CymaBay Therapeutics for $4.3 billion, adding seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to its liver portfolio. Seladelpar, with FDA priority review and anticipated U.S. approval in the third quarter of 2024, has shown promising results in Phase 3 trials, offering a potential treatment for PBC, a rare liver disease. The acquisition aligns with Gilead's commitment to addressing unmet needs in liver diseases and is expected to enhance its revenue growth upon FDA approval of seladelpar.
